Yvonne Goh

Director of Finance/CFO at CYTOMED THERAPEUTICS LIMITED

Net worth: 26 554 $ as of 2026-06-29

37 year

Distribution Services

Health Technology

Profile

Yvonne Goh worked as a Senior Executive-Finance at Leeden National Oxygen Ltd. from 2010 to 2015.
From 2015 to 2020, Ms. Goh was a Finance Manager at SBI Offshore Ltd. Former jobs include Senior Executive-Finance at Leeden National Oxygen Ltd. and Finance Manager at SBI Offshore Ltd.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
CYTOMED THERAPEUTICS LIMITED 0.22%	2026-03-30	25,781 ( 0.22% )	26 554 $	2026-06-29

Yvonne Goh active positions

Companies	Position	Start
CYTOMED THERAPEUTICS LIMITED	Director of Finance/CFO	2020-02-29

All active positions of Yvonne Goh

Former positions of Yvonne Goh

Companies	Position	End
SBI OFFSHORE LIMITED	Director of Finance/CFO	2020-02-11
Leeden National Oxygen Ltd. Leeden National Oxygen Ltd. Wholesale DistributorsDistribution Services Operates as an investment holding company with interest in distribution of industrial equipment, hardware and safety products	Director of Finance/CFO	2015-01-01

See the detail of Yvonne Goh's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Yvonne Goh's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
Leeden National Oxygen Ltd. Leeden National Oxygen Ltd. Wholesale DistributorsDistribution Services Operates as an investment holding company with interest in distribution of industrial equipment, hardware and safety products	Distribution Services
SBI Offshore Ltd. SBI Offshore Ltd. Wholesale DistributorsDistribution Services Operates as a holding company whose subsidiaries provides integrated drilling equipment and engineering solutions	Distribution Services
CytoMed Therapeutics Ltd. CytoMed Therapeutics Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biopharmaceutical company that focuses on harnessing licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers	Health Technology